CONMED Corporation (CNMD) on Wednesday, reported higher net income for the third quarter of 2026 compared with the same period a year earlier, despite a slight decline in net sales.
Net income increased to $19.796 million, or $0.66 per share, from $2.859 million, or $0.09 per share, in the third quarter of 2025. Net sales declined to $335.557 million from $337.926 million. Gross profit increased to $189.148 million from $166.119 million, while income from operations rose to $37.144 million from $11.879 million.
For the first nine months, net income increased to $56.695 million from $30.316 million, while net sales declined to $996.090 million from $1.002 billion. Earnings per share rose to $1.87 from $0.97.
CONMED updated its 2026 guidance and now expects net sales of $1.360 billion to $1.366 billion, compared with its prior range of $1.358 billion to $1.373 billion. Adjusted EPS is now expected at $4.54 to $4.61, versus the previous range of $4.48 to $4.60.
CNMD is currently trading after hours at $45.85 up $0.09 or 0.19 percent on the Nasdaq.
For comments and feedback contact: [email protected]
Business News
October 27, 2026 07:42 ET November brings a new lineup of FDA regula...